James Trager, PhD, NKarta Therapeutics, South San Francisco, CA, describes NKX019, an investigational allogeneic natural killer (NK) cell-based cancer immunotherapy expanded from healthy donor blood and engineered with a chimeric antigen receptor (CAR) that targets tumors expressing the CD19 antigen for the treatment of B-cell malignancies. NKX019 is also engineered with membrane-bound form of the IL15 cytokine which has been demonstrated to enhance the proliferation and persistence of NK cells in preclinical models. This interview took place during the CAR-TCR Summit Europe 2021.